stockrow
Monday 9 November 2026
Export TARA’s income statement to Excel — free account
Protara Therapeutics, Inc.
TARA- EPS
- −2.86%
- Free cash flow
- −28.1%
Quarter to June 2026, against a year earlier
2.30
0.17
+7.98%
Follow TARA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 72 | +7,084.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) | (70) | +8.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) | (70) | +8.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (68.80) | (85.20) | (46.00) | (3.04) | (4.70) | (4.21) | (5.86) | (3.57) | (2.17) | (1.34) | (1.35) | (35.4%) | ||||||
| Cash flow | (57.20) | (51.75) | (51.33) | (1.94) | (3.24) | (3.07) | (2.35) | (3.31) | (1.74) | (1.32) | (1.08) | (34.2%) | ||||||
| Capex | (0.65) | (0.08) | (0.26) | (0.18) | (0.12) | (0.05) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | (46.9%) | ||||||
| Free cash flow | (57.86) | (51.83) | (51.60) | (2.13) | (3.36) | (3.12) | (2.36) | (3.32) | (1.74) | (1.32) | (1.09) | (34.3%) | ||||||
| Book value | 92.83 | 80.43 | 45.17 | (0.83) | 27.54 | 14.41 | 9.07 | 6.03 | 8.12 | 4.59 | 2.64 | (28.4%) | ||||||
| Shares, m | 0 | 0 | 0 | 3 | 7 | 11 | 11 | 11 | 21 | 43 | 51 | +67.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (24) | (22) | (23) | (5) | (23) | (35) | (26) | (38) | (36) | (56) | (66) | +10.1% | |||||
| Capex | 0 | 0 | 0 | 0 | (1) | (1) | 0 | 0 | 0 | 0 | 0 | (11.1%) | ||||||
| Free cash flow | (24) | (22) | (23) | (5) | (24) | (35) | (27) | (38) | (36) | (56) | (67) | +10.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 38 | 34 | 20 | (3) | 167 | 89 | 80 | 63 | 161 | 149 | 133 | +16.5% | |||||
| Net debt | (41) | (42) | (22) | (1) | (169) | (91) | (84) | (66) | (170) | (156) | (142) | +15.9% | ||||||
| Shareholders’ equity | 38 | 35 | 20 | (2) | 199 | 162 | 102 | 68 | 167 | 196 | 161 | +19.9% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (51.37) | (83.91) | (61.42) | (63.29) | (33.25) | (25.15) | (46.14) | (42.05) | (34.25) | (29.39) | (42.05) | +22.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (70.36) | (41.99) | (236.63) | (994.46) | 0.00 | (98.74) | (255.06) | (98.7) pt | ||||||
| ROE | (56.02) | (142.13) | (341.61) | 488.15 | (34.48) | (26.17) | (49.96) | (47.44) | (37.88) | (31.60) | (45.80) | +24.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 19 | 16 | 17 | 12 | 29 | 32 | 25 | 27 | 33 | 51 | — | +11.6% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2014 · latest quarter Sep 2014
Protara Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. | $152.6M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | |
| SPRB Spruce Biosciences, Inc. | $133.8M | — (loss-making) | — (loss-making) | −75.86% (below 0%: shrinking) | n/m | −152.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MENS Jyong Biotech Ltd. | $133.6M | — | — | — | — | — | — | — | Compare |
| PDSB PDS Biotechnology Corporation | $129.2M | — (loss-making) | — | — | n/m | +69.32% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $119.2M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +11.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $134.9M | — | — | −17.64% | — | −26.05% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 2.66m | 2.31m | 198.88 |
| 2024 | 1.79m | 4.39m | 197.01 |
| 2023 | 1.91m | 1.27m | 69.96 |
Ownership
Directors and executive officers, together
7.60%
Janus Henderson
9.30%
Millennium Management LLC
5.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement